118289-16-0

Basic information

• Product Name: 2-Bromopyridine-4-methanol
• Synonyms: 2-BROMO-4-(HYDROXYMETHYL)PYRIDINE;2-BROMO-4-PYRIDINE METHANOL;(2-BROMO-PYRIDIN-4-YL)-METHANOL;2-BROMOPYRIDINE-4-METHANOL;RARECHEM AL BD 1524;2-Bromopyridine-4-methanol ,96%;Bromopyridine-4-Methanol;4-Pyridinemethanol, 2-bromo-
• CAS NO: 118289-16-0
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• EINECS: -0
• Product Categories: Hydroxymethyl's;Pyridines;Pyridine;Building Blocks;NULL;Heterocycle-Pyridine series
• Mol File: 118289-16-0.mol

Chemical Properties

• Melting Point: 58-61°C
• Boiling Point: 316.6 °C at 760 mmHg
• Flash Point: 145.3 °C
• Appearance: /
• Density: 1.668 g/cm³
• Vapor Pressure: 0.000171mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 13.06±0.10(Predicted)
• BRN: 4244047
• CAS DataBase Reference: 2-Bromopyridine-4-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromopyridine-4-methanol(118289-16-0)
• EPA Substance Registry System: 2-Bromopyridine-4-methanol(118289-16-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36-37-22
• WGK Germany: 1
• HazardClass: IRRITANT
• Hazardous Substances Data: 118289-16-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromopyridine-4-methanol is used as a synthetic intermediate for the development of antitubercular drugs. Specifically, it is utilized in the synthesis of azaand diazabiphenyl analogs of the drug (6S)-2-nitro-6-[4-(trifluoromethoxy)benzyl]oxy-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). This application is due to its ability to be incorporated into the molecular structure of PA-824, enhancing its antitubercular properties.
Additionally, 2-Bromopyridine-4-methanol is used as a synthetic intermediate for the development of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine. These analogues possess antiproliferative properties, making them potential candidates for the treatment of various proliferative disorders, including cancer.

InChI:InChI=1/C6H6BrNO/c7-6-3-5(4-9)1-2-8-6/h1-3,9H,4H2

Upstream product

• 66572-56-3 2-bromoisonicotinic acid 
• 26156-48-9 methyl 2-bromoisonicotinate 
• 695-34-1 2-Amino-4-methylpyridine 
• 4926-28-7 2-Bromo-4-picoline 
• 118289-17-1 2-bromopyridine-4-carboxaldehyde 
• 67-56-1 methanol 
• 55369-05-6 N-methoxy-2-methylpyridinium methosulphate 

Downstream Products

• 118289-17-1 2-bromopyridine-4-carboxaldehyde 
• 935861-32-8 (2-(3-methoxyphenyl)pyridin-4-yl)methoxy-tert-butyldimethylsilane 
• 482375-98-4 (2-(3-methoxyphenyl)pyridin-4-yl)methanol 
• 482375-99-5 4-chloromethyl-2-(3-methoxyphenyl)pyridine 
• 108338-10-9 2'-Bromo-2,6-dimethyl-1,4-dihydro-[4,4']bipyridinyl-3,5-dicarboxylic acid 5-[2-(benzyl-methyl-amino)-ethyl] ester 3-methyl ester 
• 1030829-16-3 (2-phenoxypyridin-4-yl)methanol 
• 32938-44-6 2-bromo-4-(bromomethyl)pyridine hydrobromide 
• 1261819-36-6 {2-[2-(trifluoromethyl)phenyl]pyridin-4-yl}methanol 
• 312325-74-9 (2-Bromopyridin-4-yl)acetonitrile 
• 1279815-46-1 1-(2-bromopyridin-4-yl)-cyclopropanecarbonitrile 
• 1295298-11-1 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(2-bromopyridin-4-yl)cyclopropyl]amide 
• 83004-14-2 2-bromo-4-bromomethyl pyridine 
• 4634-12-2 4-(hydroxymethyl)-2-phenylpyridine 
• 864460-68-4 2-bromo-4-(chloromethyl)pyridine 

Relevant articles and documents

LOX ENZYME INHIBITING METHODS AND COMPOSITIONS

This invention relates to compounds, pharmaceutical compositions and their use for treating fibrotic disorders, proliferative disorders, cardiovascular diseases, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, or neurological and neuropsychiatric conditions. One particular aspect of the inventions relates to inhibitors of the family of lysyl oxidase enzymes and their use as therapeutics for fibrotic disorders.

Photochemical C-H Silylation and Hydroxymethylation of Pyridines and Related Structures: Synthetic Scope and Mechanisms

Considering the synthetic relevance of heteroarenes in various areas ranging from organic synthesis to medicinal chemistry, developing practically simple methodologies to access functionalized heteroarenes is of a significant value. Described herein is an efficient approach for C-H silylation and hydroxymethylation of pyridines and related heterocycles by the combination of silanes or methanol with readily available N-methoxypyridinium ions with a low catalyst loading (2 mol %) under blue light irradiation. The synthetic importance of the developed reactions is demonstrated by the synthesis of biologically relevant compounds. Electron paramagnetic resonance spectroscopy, quantum yield measurements, and density-functional theory calculations allowed us to understand reaction mechanisms of both photocatalytic reactions.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Antibacterial Compounds

The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE

The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS

The invention relates to aminotriazole derivatives of formula (I), wherein A, E, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds. The compounds are useful for the prevention or treatment of diseases, which respond to the modulation of the ALX receptor such as inflammatory diseases.

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.

Substituted (Pyridylmethoxy)naphthalenes as potent and orally active 5- Lipoxygenase inhibitors: Synthesis, biological profile, and pharmacokinetics of L-739,010

Dioxabicyclooctanyl naphthalenenitriles have been reported as a class of potent and nonredox 5-lipoxygenase (5-LO) inhibitors. These bicyclo derivatives were shown to be metabolically more stable than their tetrahydropyranyl counterparts but were not well orally absorbed. Replacement of the phenyl ring in the naphthalenenitrile 1 by a pyridine ring leads to the potent and orally absorbed inhibitor 3g (L-739,010, 2-cyano-4-(3-furyl)- 7-[[6-[3-(3-hydroxy-6,8-dioxabicyclo[3.2.1]octanyl)]-2- pyridyl]methoxy]naphthalene). Compound 3g inhibits 5-HPETE production by human 5-LO and LTB4 biosynthesis by human PMN leukocytes and human whole blood (IC50s of 20, 1.6, and 42 nM, respectively). Derivative 3g is orally active in the rat pleurisy model (inhibition of LTB4, ED50 = 0.3 mg/kg) and in the anesthetized dog model (inhibition of ex vivo whole blood LTB4 and urinary LTB4, ED50 = 0.45 and 0.23 μg/kg/min, respectively, iv infusion). In addition, 3g shows excellent functional activity against ovalbumin-induced dyspnea in rats (60% inhibition at 0.5 mg/kg, 4 h pretreatment) and Ascaris-induced bronchoconstriction in conscious sheep (50% and >85% inhibition in early and late phases, respectively at 2.5 μg/kg/min, iv infusion) and, more particularly in the conscious antigen sensitive squirrel monkey model (53% inhibition of the increase in R(L) and 76% in the decrease of C(dyn), at 0.1 mg/kg, po). In rats and dogs, 3g presents excellent pharmacokinetics (estimated half-lives of 5 and 16 h, respectively) and bioavailabilities (26% and 73% when dosed as its hydrochloride salt at doses of 20 and 10 mg/kg, respectively, in methocel suspension). Based on its overall biological profile, compound 3g has been selected for preclinical animal toxicity studies.